ArticleJournal of the National Cancer Institute2019
Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Are There Socio-Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review.Cancer medicine · 2026Pooled it
- Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.Journal of the National Cancer Institute · 2024Pooled it
- Multiple Primary Cancer Incidence by County-Level Smoking Prevalence among U.S. Cancer Survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- The patient journey and guideline-concordant care in colorectal cancer-is current practice enough?Frontiers in medicine · 2026Article
- Article
- Equity and Opportunities in Lung Cancer Care-Addressing Disparities, Challenges, and Pathways Forward.Cancers · 2025Review
- Review
- Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.Journal of the National Cancer Institute · 2025Article
- Article
- Pulmonologists' Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer.Chest · 2024Article
- Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.JCO oncology practice · 2024Review
- Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.Cancer research communications · 2024Article
- Mixed Methods Evaluation of Gaps and Barriers in Delivery of Precision Oncology in Advanced Lung Cancer.Journal of oncology navigation & survivorship · 2024Article
- Disparities in Lung Cancer: A Targeted Literature Review Examining Lung Cancer Screening, Diagnosis, Treatment, and Survival Outcomes in the United States.Journal of racial and ethnic health disparities · 2024Review
- Disparities in care of older adults of color with cancer: A narrative review.Cancer medicine · 2024Review
- Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.Cancer medicine · 2023Article
- Factors leading to disparity in lung cancer diagnosis among black/African American communities in the USA: a qualitative study.BMJ open · 2023Article
- Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).JCO precision oncology · 2023Article
- Understanding inequities in precision oncology diagnostics.Nature cancer · 2023Review
- Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non-Small Cell Lung Cancer and Colorectal Cancer.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Data are limited regarding whether the availability of biomarker-directed therapy for lung cancer exacerbates racial and socioeconomic disparities. Patients diagnosed with stage IV lung adenocarcinoma from 2008 to 2013 were identified using Surveillance, Epidemiology, and End Results Program-Medicare. The primary outcome was a Medicare claim for molecular testing within 60 days of diagnosis, analyzed using multivariable logistic regression; the secondary outcome was overall survival, analyzed using multivariable Cox proportional hazards models. All statistical tests were two-sided. Of 5556 patients, 1437 (25.9%) had molecular testing. Testing rates were 14.1% among black, 26.2% among white, and 32.8% among patients of Asian/other descent (adjusted P < .001); 20.6% among patients with Medicaid eligibility vs 28.4% among those without (adjusted P = .01); and 19.9% among patients in the highest census tract-level poverty rate quintile vs 30.7% among patients in the lowest quintile (for all quintiles, adjusted P = .18). Median survival from 60 days was 8.2 months among patients with molecular testing within 60 days of diagnosis and 6.1 months among those without (hazard ratio = 0.92, 95% confidence interval = 0.86 to 0.99; adjusted P = .02). Equitable precision medicine requires concerted implementation efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.